M&A / Deals Sidewinder pockets $137m in Series B to take bispecific ADCs to clinic Pharmaceutical TechnologyThe funding round, led by Novartis and OrbiMed, will allow Sidewinder to progress its bispecific ADC programmes to the clinic.M&A / DealsOncologyRead full story pharminent April 8, 2026 (Last updated: April 8, 2026) Pharmaceutical Technology The funding round, led by Novartis and OrbiMed, will allow Sidewinder to progress its bispecific ADC programmes to the clinic. M&A / DealsOncologyRead full story Post navigation Previous: Activist investor renews its criticism of NovavaxNext: Medicare Advantage Insurers Will See Higher Payments as CMS Backs Off a Key Payment Update Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
